Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers.

Suryavathi ViswanadhapalliShihong MaGangadhara Reddy SareddyTae-Kyung LeeMengxing LiCollin GilbreathXihui LiuYiliao LuoUday P PratapMei ZhouEliot B BlattKara KasseesCarlos ArteagaPrasanna AlluriManjeet RaoSusan T WeintraubRajeshwar Rao TekmalJung-Mo AhnGanesh V RajRatna K Vadlamudi

Published in: Breast cancer research : BCR (2019)

Our results suggest that ERX-11 inhibited the proliferation of BCa cells resistant to both endocrine therapy and CDK4/6 inhibitors in a dose-dependent manner and that the combination of ERX-11 with a CDK4/6 inhibitor may represent a viable therapeutic approach.

Keyphrases

estrogen receptor
cell cycle
induced apoptosis
cell cycle arrest
signaling pathway
stem cells
cell death
oxidative stress
young adults
bone marrow
dna binding